Edition:
United Kingdom

People: Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

2.30USD
13 Dec 2018
Change (% chg)

$-0.18 (-7.26%)
Prev Close
$2.48
Open
$2.52
Day's High
$2.58
Day's Low
$2.28
Volume
3,550,660
Avg. Vol
1,439,002
52-wk High
$2.75
52-wk Low
$1.05

Herrmann, John 

Mr. John A. Herrmann, III is the Senior Vice President, General Counsel, Corporate Secretary of the Company. He previously served as the Company’s Vice President, General Counsel and Corporate Secretary from March 2012 to June 2014, and its Executive Director, Legal Affairs and Corporate Secretary from April 2010 to March 2012. Prior to joining the Company, Mr. Herrmann was General Counsel at Ore Pharmaceuticals and Deputy General Counsel at Gene Logic before it became Ore Pharmaceuticals. Mr. Herrmann worked as Senior Counsel for Celera Genomics following his position as Senior Corporate Counsel at Baxter Healthcare in its Renal Division. Mr. Herrmann received a B.A. in political science and history from Brown University and a J.D. from the University of Illinois.

Basic Compensation

Total Annual Compensation, USD 478,550
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 434,767
Fiscal Year Total, USD 913,317

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

James Young

533,780

Stanley Erck

2,771,680

John Trizzino

947,747

Gregory Glenn

1,221,250

John Herrmann

913,317

Jody Lichaa

--
As Of  31 Dec 2017